Fig. 5: Interleukin-3 promotes the recruitment of pDCs into the lung in a CXCL12-dependent manner.

a Relative mRNA expression of Cxcl12 in the lungs of naive mice 24 h after the i.n. injection of PBS or rIL-3. p = 0.0009. n = 11–12. b Level of CXCL12 in the BALF of WT or Cd131^−/− mice 24 h after the i.n. injection of PBS or rIL-3. n = 7 for WT (p = 0.0416) and n = 8 for Cd131^−/− (p = 0.8046). c Absolute number of pDCs and neutrophils in the lungs of naive mice 24 h after the i.n.injection of PBS, IgG or anti-CXCL12 followed by i.n. injection of PBS (black) or IL-3 (grey). p = 0.0371 for IgG vs αCXCL12 and p = 0.437 for PBS vs IgG. n = 8–9. d Correlation between plasma IL-3 and CXCL12 levels of SARS-CoV-2⁺ patients. n = 181. e Level of CXCL12 in the BALF of patients with pulmonary diseases with high or low IL-3 BALF levels. p = 0.0078. n = 13. f Percentage of pDCs in the BALF of patients with pulmonary diseases with high or low CXCL12 BALF levels. p = 0.0051. n = 12. g Percentage of CXCL12⁺ epithelial cells in the lungs of patients with pulmonary inflammation. p < 0.0001. n = 16. h Immunohistochemistry of CD123, EpCAM, CXCL12, CD31, and IgG in the lungs of patients with pulmonary inflammation. n = 3 different lungs. Data are mean ± S.E.M., *P < 0.05, **P < 0.01, ***P < 0.001, two-tailed unpaired or Mann–Whitney test were used. Source data are provided as a Source Data file.